Source:http://linkedlifedata.com/resource/pubmed/id/15489879
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0001792,
umls-concept:C0003442,
umls-concept:C0009647,
umls-concept:C0010583,
umls-concept:C0012634,
umls-concept:C0023473,
umls-concept:C0030705,
umls-concept:C0059985,
umls-concept:C0750729,
umls-concept:C0876926,
umls-concept:C0884358,
umls-concept:C1274040,
umls-concept:C1551022,
umls-concept:C1552913,
umls-concept:C1961136,
umls-concept:C1999230
|
| pubmed:issue |
12
|
| pubmed:dateCreated |
2004-12-1
|
| pubmed:abstractText |
Allogeneic bone marrow or stem cell transplantation is a curative therapeutic option for chronic myelogenous leukemia. In order to decrease the toxicity of the procedure, the dosage of total body irradiation was reduced from 12 to 8 Gy and subsequently the dose of cyclophosphamide from 120 to 80 mg/kg. The purine analogue fludarabine, ATG, cyclosporine A and a short course of methotrexate were given for immune suppression. So far, 35 elderly CML patients with sibling and unrelated donors have been transplanted. Transplant-related mortality at day + 100 was 11%. After engraftment, all patients achieved a complete cytogenetic remission. Relapse occurred in 14% of the patients. The risk of relapse was significantly higher in those patients transplanted in second chronic or accelerated phase (P = 0.048). After a median follow-up of 30 months (range 12-62), 63% of the patients are alive. Those patients transplanted within the first year from diagnosis had an overall survival of 79% (P = 0.049), emphasizing the benefit of early transplantation. Stepwise reduction of conditioning intensity resulted in stable engraftment, low relapse rates and encouraging overall survival in this high-risk patient group.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:copyrightInfo |
Bone Marrow Transplantation (2004).
|
| pubmed:issnType |
Print
|
| pubmed:volume |
34
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1083-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15489879-Antilymphocyte Serum,
pubmed-meshheading:15489879-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15489879-Combined Modality Therapy,
pubmed-meshheading:15489879-Cyclophosphamide,
pubmed-meshheading:15489879-Dose-Response Relationship, Radiation,
pubmed-meshheading:15489879-Female,
pubmed-meshheading:15489879-Follow-Up Studies,
pubmed-meshheading:15489879-Graft Survival,
pubmed-meshheading:15489879-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:15489879-Humans,
pubmed-meshheading:15489879-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:15489879-Male,
pubmed-meshheading:15489879-Middle Aged,
pubmed-meshheading:15489879-Recurrence,
pubmed-meshheading:15489879-Survival Analysis,
pubmed-meshheading:15489879-Time Factors,
pubmed-meshheading:15489879-Transplantation, Homologous,
pubmed-meshheading:15489879-Transplantation Conditioning,
pubmed-meshheading:15489879-Vidarabine,
pubmed-meshheading:15489879-Whole-Body Irradiation
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease.
|
| pubmed:affiliation |
Clinical Cooperative Group for Haematopoietic Cell Transplantation, Department of Medicine III, University of Munich, Klinikum Grosshadern, Marchioninistr. 5, 81377 Munich, Germany. martin.weisser@med.uni-muenchen.de
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|